Clinical Trial Update: A Renal Impairment Study for PF-06651600 [Phase 1]

View source ↗

Summary

Phase 1 renal impairment study of PF-06651600 was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• PF-06651600 (PF-06651600)

Snippet

Sponsor: Pfizer | Conditions: Renal Impairment | Phase 1 | Status: TERMINATED | Results posted: 2021-05-18